Podsumowanie

Terapia obniżająca stężenia lipidów w surowicy ma ugruntowaną pozycję zarówno w profilaktyce pierwotnej, jak i wtórnej chorób układu sercowo-naczyniowego, które są związane z procesami miażdżycowymi. Istnieją ponadto badania, w których wykazano, że u pacjentów w ostrych stanach infekcyjnych, także w przypadku COVID-19, terapia hipolipemizująca (szczególnie statynami) poprawiała rokowanie. Należy więc, jeśli to tylko możliwe, kontynuować stosowaną wcześniej terapię obniżającą stężenie cholesterolu. COVID-19 to schorzenie wywołane pojawieniem się nowego patogenu. Może się okazać, że po przeprowadzeniu kolejnych, dobrze zaprojektowanych badań będą potrzebne nowe zalecenia dotyczące farmakoterapii zaburzeń lipidowych u pacjentów zakażonych SARS-CoV-2.

ABSTRACT

How lipid-lowering therapy affects COVID-19 presentation?

Lipid-lowering therapy has a well-established role in both primary and secondary prevention of atherosclerotic cardiovascular diseases. There are also studies that have shown that in patients with acute infectious conditions, including COVID-19, lipid-lowering therapy, especially statins, help to improve the patient’s prognosis. Therefore, previous lipid-lowering medications should be continued whenever possible. COVID-19 is a disease caused by a new pathogen. After some time and more clinical trials, we will possibly see new recommendations for the pharmacotherapy of dyslipidemia during the pandemic.

Piśmiennictwo

  1. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation, and Treatment of Coronavirus. Updated 2020 Oct 4. In: StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK554776/ [dostęp: 05.12.2020]
  2. Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, et al. A comprehensive review of COVID-19 characteristics. Biol Proced Online 2020;22:19
  3. Alwan NA, Burgess RA, Ashworth S, et al. Scientific consensus on the COVID-19 pandemic: we need to act now. Lancet 2020;396(10260):e71-2
  4. Worldometer. COVID-19. Coronavirus pandemic. https://www.worldometers.info/coronavirus/? [dostęp: 05.12.2020]
  5. John Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE). https://coronavirus.jhu.edu/map.html [dostęp: 05.12.2020]
  6. Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int J Infect Dis 2020;101:138-48
  7. World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/, The push for a COVID-19 vaccine https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines [dostęp: 05.12.2020]
  8. European Centre for Disease Prevention and Control. Communicable disease threats report, 22-28 November 2020, week 48. https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-22-28-november-2020-week-48 [dostęp: 05.12.2020]
  9. Ministerstwo Zdrowia. Koronawirus: informacje i zalecenia. Aktualne zasady i ograniczenia. https://www.gov.pl/web/koronawirus/aktualne-zasady-i-ograniczenia; Polska przygotowuje się na zakup i przyjęcie szczepionki na COVID-19 https://www.gov.pl/web/koronawirus/polska-przygotowuje-sie-na-zakup-i-przyjecie-szczepionki-na-covid-19 [dostęp: 05.12.2020]
  10. Komisja Europejska. Komunikat Komisji do Parlamentu Europejskiego i Rady. Gotowość w obszarze strategii szczepień i wprowadzania szczepionek przeciwko COVID-19. https://eur-lex.europa.eu/legal-content/PL/TXT/PDF/?uri=CELEX:52020DC0680&from=PL [dostęp: 05.12.2020]
  11. Li M, Cheng B, Zeng W, et al. Analysis of the Risk Factors for Mortality in Adult COVID-19 Patients in Wuhan: A Multicenter Study. Front Med (Lausanne) 2020;7:545
  12. Maddaloni E, D’Onofrio L, Alessandri F, et al. Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovasc Diabetol 2020;19(1):164
  13. Nachtigall I, Lenga P, Jóźwiak K, et al. Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect 2020;26(12):1663-9
  14. Parohan M, Yaghoubi S, Seraji A, et al. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of observational studies. The Aging Male 2020;5:1-9
  15. Timmis A, Townsend N, Gale C, et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J 2018;39(7):508-79
  16. Laufs U, Dent R, Kostenuik PJ, et al. Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine. Eur Heart J 2019;40(33):2825-30
  17. Cybulska B, Kłosiewicz-Latoszek L, Szostak W. Hipercholesterolemia. Interna Szczeklika. https://www.mp.pl/interna/chapter/B16.II.2.4.1 [dostęp: 05.12.2020]
  18. Filipiak KJ, Sokólski M. Leki hipolipemizujące – mechanizmy działania, dobór, kojarzenie i dawkowanie. Choroby Serca i Naczyń 2017;14(5):283-7
  19. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111-88
  20. Rozuwastatyna (rosuvastatin). Indeks leków. Medycyna Praktyczna. https://indeks.mp.pl/desc.php?id=7934&id=7934 [dostęp: 05.12.2020]
  21. Ezetymib (ezetimibe). Indeks leków. Medycyna Praktyczna. https://indeks.mp.pl/desc.php?id=5610 [dostęp: 05.12.2020]
  22. Fenofibrat (fenofibrate). Indeks leków. Medycyna Praktyczna. https://indeks.mp.pl/desc.php?id=290 [dostęp: 05.12.2020]
  23. Ewolokumab (evolocumab). Indeks leków. Medycyna Praktyczna. https://indeks.mp.pl/desc.php?id=15523 [dostęp: 05.12.2020]
  24. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:III39-43
  25. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017;120:229-43
  26. Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-Cholesterol lowering. Am J Cardiovasc Drugs 2010;10:10-7
  27. Kow CS, Hasan SS. Meta-analysis of Effect of Statins in Patients with COVID-19. Am J Cardiol 2020;134:153-5
  28. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012;8:415-27
  29. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and metaanalysis of randomized controlled trials. J Intern Med 2009;265:568-80
  30. Israel A, Schaffer A, Cicurel A, et al. Large population study identifies drugs associated with reduced COVID-19 severity. Preprint. MedRxiv 2020. https://www.medrxiv.org/content/10.1101/2020.10.13.20211953v2 [dostęp: 05.12.2020]
  31. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97
  32. Keene D, Price C, Shun Shin MJ, et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014;349:g4379
  33. Buschard K. Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. Med Hypotheses 2020;143:110127
  34. Takahashi T, Ito K, Fukushima K, et al. Sulfatide negatively regulates the fusion process of human parainfluenza virus type 3. J Biochem 2012;152(4):373-80
  35. Kilicarslan A, Yavuz B, Guven GS, et al. Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome. Blood Coagul Fibrinolysis 2008;19(4):310-4
  36. Karunakaran KB, Balakrishnan N, Ganapathiraju M. Potentially repurposable drugs for COVID-19 identified from SARS-CoV-2 Host Protein Interactome. Preprint. Res Sq 2020;rs.3.rs-30363
  37. Alleva LM, Budd AC, Clark IA. Minimising Influenza Disease with Fibrates. Int J Infect Dis 2008;12:e176
  38. Chirinos JA. FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019. https://clinicaltrials.gov/ct2/show/NCT04517396 [dostęp: 05.12.2020]
  39. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 2014;54:273-93
  40. Scicali R, Di Pino A, Piro S, et al. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects? Nutr Metab Cardiovasc Dis 2020;30(7):1068-9
  41. Vuorio A, Kovanen PT. PCSK9 inhibitors for COVID-19: An opportunity to enhance the antiviral action of interferon in patients with hypercholesterolemia. J Intern Med 2020 Nov 21. Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/33222314/ [dostęp: 05.12.2020]
  42. Vuorio A, Kovanen PT. Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia. J Clin Lipidol 2020;14(5):617-8
  43. Banach M, Penson PE, Fras Z, et al. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. Pharmacol Res 2020;158:104891
  44. European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance [dostęp: 05.12.2020]
  45. Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis 2020;313:126-36
  46. Douglas I, Evans S, Smeeth L. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ 2011;342:d1642
  47. Fleming DM, Verlander NQ, Elliot AJ, et al. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect 2010;138(9):1281-8
  48. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med 2013;158(7):526-34
  49. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40(5):998-1004
  50. Mohamed MFH, Salameh OK, Saeed AAM. Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death. Am J Case Rep 2019;20:709-12
  51. Dixon DL, Van Tassell BW, Vecchié A, et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). J Cardiovasc Pharmacol 2020;75(5):359-67
  52. Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int 2020;14(5):881-3
  53. Vuorio A, Watts GF, Kovanen PT. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. J Intern Med 2020;287(6):746-7
Do góry